{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:43:03Z","timestamp":1791229383487,"version":"4.1.0"},"reference-count":218,"publisher":"Harborside Press, LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:p>\n                    Eosinophilic disorders and related syndromes represent a heterogeneous group of neoplastic and nonneoplastic conditions, characterized by more eosinophils in the peripheral blood, and may involve eosinophil-induced organ damage. In the WHO classification of myeloid and lymphoid neoplasms, eosinophilic disorders characterized by dysregulated tyrosine kinase (TK) fusion genes are recognized as a new category termed,\n                    <jats:italic>myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of<\/jats:italic>\n                    PDGFRA\n                    <jats:italic>,<\/jats:italic>\n                    PDGFRB\n                    <jats:italic>or<\/jats:italic>\n                    FGFR1\n                    <jats:italic>or with<\/jats:italic>\n                    PCM1-JAK2\n                    <jats:italic>.<\/jats:italic>\n                    In addition to these aforementioned TK fusion genes, rearrangements involving\n                    <jats:italic>FLT3<\/jats:italic>\n                    and\n                    <jats:italic>ABL1<\/jats:italic>\n                    genes have also been described. These new NCCN Guidelines include recommendations for the diagnosis, staging, and treatment of any one of the myeloid\/lymphoid neoplasms with eosinophilia (MLN-Eo) and a TK fusion gene included in the 2017 WHO Classification, as well as MLN-Eo and a\n                    <jats:italic>FLT3<\/jats:italic>\n                    or\n                    <jats:italic>ABL1<\/jats:italic>\n                    rearrangement.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2020.0042","type":"journal-article","created":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T15:22:03Z","timestamp":1599232923000},"page":"1248-1269","source":"Crossref","is-referenced-by-count":44,"title":["Myeloid\/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology"],"prefix":"10.6004","volume":"18","author":[{"given":"Aaron T.","family":"Gerds","sequence":"first","affiliation":[{"name":"1Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"2Stanford Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"3The University of Texas MD Anderson Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dunbar","sequence":"additional","affiliation":[{"name":"5Memorial Sloan Kettering Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Elshoury","sequence":"additional","affiliation":[{"name":"6Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy I.","family":"George","sequence":"additional","affiliation":[{"name":"4Huntsman Cancer Institute at the University of Utah;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Gojo","sequence":"additional","affiliation":[{"name":"7The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Gundabolu","sequence":"additional","affiliation":[{"name":"8Fred & Pamela Buffett Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"9Abramson Cancer Center at the University of Pennsylvania;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Hobbs","sequence":"additional","affiliation":[{"name":"10Massachusetts General Hospital Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Jain","sequence":"additional","affiliation":[{"name":"7The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catriona","family":"Jamieson","sequence":"additional","affiliation":[{"name":"11UC San Diego Moores Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Kuykendall","sequence":"additional","affiliation":[{"name":"12Moffitt Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"McMahon","sequence":"additional","affiliation":[{"name":"13University of Colorado Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay R.","family":"Mohan","sequence":"additional","affiliation":[{"name":"14Vanderbilt-Ingram Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Oehler","sequence":"additional","affiliation":[{"name":"15Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Oh","sequence":"additional","affiliation":[{"name":"16Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"17Mayo Clinic Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Podoltsev","sequence":"additional","affiliation":[{"name":"18Yale Cancer Center\/Smilow Cancer Hospital;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Ranheim","sequence":"additional","affiliation":[{"name":"19University of Wisconsin Carbone Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Rein","sequence":"additional","affiliation":[{"name":"20Duke Cancer Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Salit","sequence":"additional","affiliation":[{"name":"15Fred Hutchinson Cancer Research Center\/Seattle Cancer Care Alliance;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Snyder","sequence":"additional","affiliation":[{"name":"21City of Hope National Medical Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brady L.","family":"Stein","sequence":"additional","affiliation":[{"name":"22Robert H. Lurie Comprehensive Cancer Center of Northwestern University;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Talpaz","sequence":"additional","affiliation":[{"name":"23University of Michigan Rogel Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swapna","family":"Thota","sequence":"additional","affiliation":[{"name":"6Roswell Park Comprehensive Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankit","family":"Vachhani","sequence":"additional","affiliation":[{"name":"24O'Neal Comprehensive Cancer Center at UAB;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Wadleigh","sequence":"additional","affiliation":[{"name":"25Dana-Farber\/Brigham and Women\u2019s Cancer Center;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Walsh","sequence":"additional","affiliation":[{"name":"26The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn C.","family":"Ward","sequence":"additional","affiliation":[{"name":"27UCLA Jonsson Comprehensive Cancer Center; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Anne","family":"Bergman","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Sundar","sequence":"additional","affiliation":[{"name":"28National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref901","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","article-title":"PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"ref1671","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cancergen.2016.03.002","article-title":"BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia","volume":"209","author":"He","year":"2016","journal-title":"Cancer Genet"},{"key":"ref1611","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood"},{"key":"ref921","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref101","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref1051","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1731","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cancergen.2016.03.002","article-title":"BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia","volume":"209","author":"He","year":"2016","journal-title":"Cancer Genet"},{"key":"ref1071","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"key":"ref1361","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"ref1301","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MPH.0000000000001446","article-title":"Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRA rearrangement treated with imatinib mesylate: A pediatric case with long-term follow-up","volume":"41","author":"Srinivasan","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref941","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","article-title":"Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume":"4","author":"Metzgeroth","year":"2020","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WOX.0b013e31827f4192","article-title":"ICON: Eosinophil Disorders","volume":"5","author":"Valent","year":"2012","journal-title":"World Allergy Organ J"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/bjh.16340","article-title":"Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis","volume":"188","author":"Olsson-Arvidsson","year":"2020","journal-title":"Br J Haematol"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref261","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","article-title":"Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement","volume":"23","author":"Umino","year":"2018","journal-title":"Hematology"},{"key":"ref2121","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref991","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2015.136","article-title":"Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia","volume":"30","author":"Khodadoust","year":"2016","journal-title":"Leukemia"},{"key":"ref821","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"ref1241","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.5858\/arpa.2016-0223-RA","article-title":"Blood and bone marrow evaluation for eosinophilia","volume":"140","author":"Boyer","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"ref1351","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10245332.2018.1446279","article-title":"Clinical outcomes of myeloid\/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1) rearrangement","volume":"23","author":"Umino","year":"2018","journal-title":"Hematology"},{"key":"ref1661","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cancergencyto.2008.02.005","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia","volume":"183","author":"Cirmena","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"ref1061","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"key":"ref1811","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"ref2051","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"key":"ref1451","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"key":"ref2031","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/bloodadvances.2019001111","article-title":"Treatment-free remission in FIP1L1-PDGFRA-positive myeloid\/lymphoid neoplasms with eosinophilia after imatinib discontinuation","volume":"4","author":"Metzgeroth","year":"2020","journal-title":"Blood Adv"},{"key":"ref1501","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","article-title":"Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease","volume":"117","author":"Elling","year":"2011","journal-title":"Blood"},{"key":"ref961","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1038\/leu.2014.168","article-title":"ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant","volume":"28","author":"Falchi","year":"2014","journal-title":"Leukemia"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood"},{"key":"ref1171","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"key":"ref1551","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/10428194.2018.1480774","article-title":"Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome\/myeloproliferative neoplasm","volume":"60","author":"Singh","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia"},{"key":"ref831","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"ref1971","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"ref681","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ajh.24273","article-title":"Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"ref1951","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"key":"ref1631","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"ref591","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12308-014-0203-6","article-title":"ETV6 \/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia","volume":"7","author":"Hosseini","year":"2014","journal-title":"J Hematop"},{"key":"ref1891","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"ref1181","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"key":"ref1821","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.14748","article-title":"Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation","volume":"182","author":"Bidet","year":"2018","journal-title":"Br J Haematol"},{"key":"ref881","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/nsmb.1486","article-title":"Activation of tyrosine kinases by mutation of the gatekeeper threonine","volume":"15","author":"Azam","year":"2008","journal-title":"Nat Struct Mol Biol"},{"key":"ref1371","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia"},{"key":"ref1081","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"ref1771","doi-asserted-by":"crossref","first-page":"E10","DOI":"10.1002\/ajh.24273","article-title":"Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am J Hematol"},{"key":"ref1531","article-title":"Myeloid neoplasms with t(5;12) and ETV6-ACSL6 gene fusion, potential mimickers of myeloid neoplasm with PDGFRB rearrangement: case report with imatinib therapy and review of the literature [published online September 26,2016]","author":"De Luca-Johnson","journal-title":"Case Rep Med"},{"key":"ref1421","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"ref2111","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref771","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"key":"ref971","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2812.2812","article-title":"Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes","volume":"126","author":"Kreil","year":"2015","journal-title":"Blood"},{"key":"ref701","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","article-title":"Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study","volume":"28","author":"Helbig","year":"2010","journal-title":"Hematol Oncol"},{"key":"ref1191","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"ref691","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/ajh.24267","article-title":"Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"key":"ref671","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"},{"key":"ref1801","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"ref1931","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3109\/10428194.2012.749469","article-title":"Sorafenib is effective for imatinib-resistant FIP1L1\/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia","volume":"54","author":"Al-Riyami","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref1441","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"B\u00f6hm","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"ref2041","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","article-title":"Successful allogeneic stem cell transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia","volume":"93","author":"Chonabayashi","year":"2014","journal-title":"Ann Hematol"},{"key":"ref1581","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.14748","article-title":"Molecular monitoring of patients with ETV6-PDGFRB rearrangement: Implications for therapeutic adaptation","volume":"182","author":"Bidet","year":"2018","journal-title":"Br J Haematol"},{"key":"ref1151","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol"},{"key":"ref2171","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-03-343426","article-title":"Response of ETV6-FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3","volume":"118","author":"Walz","year":"2011","journal-title":"Blood"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.2010.08394.x","article-title":"Molecular characterization of paediatric idiopathic hypereosinophilia","volume":"151","author":"Rapanotti","year":"2010","journal-title":"Br J Haematol"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/sj.leu.2403879","article-title":"PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation","volume":"19","author":"Murati","year":"2005","journal-title":"Leukemia"},{"key":"ref1901","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol"},{"key":"ref911","first-page":"3027631","article-title":"von Clinical response to avapritinib by RECIST and Criteria in th line and exon gastrointestinal stromal tumors abstract Connective Tissue Oncology Meeting Japan Abstract","volume":"4","author":"HeinrichM","year":"2019","journal-title":"Society Annual"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/MPH.0b013e31827e6386","article-title":"FIP1L1-PDGFR\u03b1-positive hypereosinophilic syndrome in childhood: a case report and review of literature","volume":"36","author":"Farruggia","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref1461","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"ref1491","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2009.016345","article-title":"Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis","volume":"95","author":"Erben","year":"2010","journal-title":"Haematologica"},{"key":"ref1041","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-013-1695-3","article-title":"Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1","volume":"92","author":"Patterer","year":"2013","journal-title":"Ann Hematol"},{"key":"ref1141","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"ref711","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.leu.2403600","article-title":"Myeloid blast crisis evolving during imatinib treatment of an FIP1L1-PDGFR alpha-positive chronic myeloproliferative disease with prominent eosinophilia","volume":"19","author":"von Bubnoff","year":"2005","journal-title":"Leukemia"},{"key":"ref341","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"ref2021","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.23588","article-title":"Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome","volume":"89","author":"Helbig","year":"2014","journal-title":"Am J Hematol"},{"key":"ref951","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00277-013-1843-9","article-title":"Successful allogeneic stem cell transplantation with long-term remission of ETV6\/FLT3-positive myeloid\/lymphoid neoplasm with eosinophilia","volume":"93","author":"Chonabayashi","year":"2014","journal-title":"Ann Hematol"},{"key":"ref1121","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"ref1681","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12308-014-0203-6","article-title":"ETV6 \/FLT3 fusion in a mixed-phenotype acute leukemia arising in lymph nodes in a patient with myeloproliferative neoplasm with eosinophilia","volume":"7","author":"Hosseini","year":"2014","journal-title":"J Hematop"},{"key":"ref2071","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am J Hematol"},{"key":"ref1101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1097\/WOX.0b013e31827f4192","article-title":"ICON: Eosinophil Disorders","volume":"5","author":"Valent","year":"2012","journal-title":"World Allergy Organ J"},{"key":"ref1431","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000059404","article-title":"Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease","volume":"128","author":"Sperr","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.5858\/arpa.2016-0223-RA","article-title":"Blood and bone marrow evaluation for eosinophilia","volume":"140","author":"Boyer","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"ref1511","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1111\/bjh.16340","article-title":"Frequent false-negative FIP1L1-PDGFRA FISH analyses of bone marrow samples from clonal eosinophilia at diagnosis","volume":"188","author":"Olsson-Arvidsson","year":"2020","journal-title":"Br J Haematol"},{"key":"ref441","article-title":"Myeloid neoplasms with t(5;12) and ETV6-ACSL6 gene fusion, potential mimickers of myeloid neoplasm with PDGFRB rearrangement: case report with imatinib therapy and review of the literature [published online September 26,2016]","author":"De Luca-Johnson","journal-title":"Case Rep Med"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MPH.0000000000001446","article-title":"Myeloid neoplasm with eosinophilia and FIP1L1-PDGFRA rearrangement treated with imatinib mesylate: A pediatric case with long-term follow-up","volume":"41","author":"Srinivasan","year":"2019","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1182\/blood-2010-05-286757","article-title":"Novel imatinib-sensitive PDGFRA-activating point mutations in hypereosinophilic syndrome induce growth factor independence and leukemia-like disease","volume":"117","author":"Elling","year":"2011","journal-title":"Blood"},{"key":"ref1521","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/leu.2008.310","article-title":"The molecular anatomy of the FIP1L1-PDGFRA fusion gene","volume":"23","author":"Walz","year":"2009","journal-title":"Leukemia"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796","article-title":"FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33)","volume":"95","author":"Guasch","year":"2000","journal-title":"Blood"},{"key":"ref841","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3109\/10428194.2012.749469","article-title":"Sorafenib is effective for imatinib-resistant FIP1L1\/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia","volume":"54","author":"Al-Riyami","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"ref1791","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"ref981","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.25825","article-title":"Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes","volume":"95","author":"Schwaab","year":"2020","journal-title":"Am J Hematol"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cancergencyto.2008.02.005","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11) in a patient with acute myeloid leukemia","volume":"183","author":"Cirmena","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5858\/arpa.2011-0597-RA","article-title":"Diagnostic complexities of eosinophilia","volume":"137","author":"Montgomery","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"ref851","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"ref1941","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2006-02-004457","article-title":"Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant","volume":"108","author":"Lierman","year":"2006","journal-title":"Blood"},{"key":"ref1981","first-page":"1263","article-title":"Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene","volume":"89","author":"Bastie","year":"2004","journal-title":"Haematologica"},{"key":"ref2151","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s00277-015-2451-7","article-title":"Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene","volume":"94","author":"Rumi","year":"2015","journal-title":"Ann Hematol"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"e0185602","DOI":"10.1371\/journal.pone.0185602","article-title":"Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"ref1751","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"key":"ref2161","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00277-014-2221-y","article-title":"Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes","volume":"94","author":"Schwaab","year":"2015","journal-title":"Ann Hematol"},{"key":"ref1321","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s00277-017-3067-x","article-title":"Imatinib in myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase","volume":"96","author":"Jawhar","year":"2017","journal-title":"Ann Hematol"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/leu.2008.310","article-title":"The molecular anatomy of the FIP1L1-PDGFRA fusion gene","volume":"23","author":"Walz","year":"2009","journal-title":"Leukemia"},{"key":"ref361","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1038\/s41375-019-0632-4","article-title":"Prognostic impact of eosinophils in mastocytosis: analysis of 2350 patients collected in the ECNM Registry","volume":"34","author":"Kluin-Nelemans","year":"2020","journal-title":"Leukemia"},{"key":"ref381","first-page":"177","article-title":"Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"125","author":"Cools","year":"2006","journal-title":"Methods Mol Med"},{"key":"ref731","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2008.309","article-title":"Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions","volume":"23","author":"Score","year":"2009","journal-title":"Leukemia"},{"key":"ref1271","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.1365-2141.2010.08394.x","article-title":"Molecular characterization of paediatric idiopathic hypereosinophilia","volume":"151","author":"Rapanotti","year":"2010","journal-title":"Br J Haematol"},{"key":"ref801","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood-2006-05-024828","article-title":"Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders","volume":"109","author":"David","year":"2007","journal-title":"Blood"},{"key":"ref1541","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1038\/leu.2017.240","article-title":"Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia","volume":"31","author":"Jawhar","year":"2017","journal-title":"Leukemia"},{"key":"ref1401","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"ref1481","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/leu.2008.309","article-title":"Detection and molecular monitoring of FIP1L1-PDGFRA-positive disease by analysis of patient-specific genomic DNA fusion junctions","volume":"23","author":"Score","year":"2009","journal-title":"Leukemia"},{"key":"ref751","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"key":"ref1911","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood-2014-02-555607","article-title":"Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib","volume":"123","author":"Cheah","year":"2014","journal-title":"Blood"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am J Hematol"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref1391","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3324\/haematol.2008.005447","article-title":"T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome","volume":"94","author":"Helbig","year":"2009","journal-title":"Haematologica"},{"key":"ref1831","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"ref311","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/MD.0b013e3182a71eba","article-title":"The spectrum of FIP1L1-PDGFRA-associated chronic eosinophilic leukemia: new insights based on a survey of 44 cases","volume":"92","author":"Legrand","year":"2013","journal-title":"Medicine (Baltimore)"},{"key":"ref1311","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Golub","year":"1994","journal-title":"Cell"},{"key":"ref741","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1182\/blood-2006-10-050054","article-title":"Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia","volume":"109","author":"Jovanovic","year":"2007","journal-title":"Blood"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2015-06-654277","article-title":"Identification of a gain-of-function STAT3 mutation (p.Y640F) in lymphocytic variant hypereosinophilic syndrome","volume":"127","author":"Walker","year":"2016","journal-title":"Blood"},{"key":"ref1561","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cancergen.2020.03.002","article-title":"Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing","volume":"244","author":"Zimmermann","year":"2020","journal-title":"Cancer Genet"},{"key":"ref721","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2141.2008.07033.x","article-title":"A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients","volume":"141","author":"Helbig","year":"2008","journal-title":"Br J Haematol"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2009.016345","article-title":"Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis","volume":"95","author":"Erben","year":"2010","journal-title":"Haematologica"},{"key":"ref1591","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000497348","article-title":"RNA sequencing analysis for the identification of a PCM1\/PDGFRB fusion gene responsive to imatinib","volume":"142","author":"Such","year":"2019","journal-title":"Acta Haematol"},{"key":"ref1781","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1002\/ajh.24267","article-title":"Targeted next generation sequencing of PDGFRB rearranged myeloid neoplasms with monocytosis","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol"},{"key":"ref1851","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"key":"ref1341","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1080\/10428194.2017.1397663","article-title":"Myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"59","author":"Strati","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"ref1211","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"ref1251","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.leu.2404662","article-title":"Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma","volume":"21","author":"Metzgeroth","year":"2007","journal-title":"Leukemia"},{"key":"ref1641","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"ref1691","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol"},{"key":"ref811","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0609.2012.01799.x","article-title":"Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement","volume":"89","author":"Arefi","year":"2012","journal-title":"Eur J Haematol"},{"key":"ref1031","doi-asserted-by":"crossref","first-page":"14479","DOI":"10.1073\/pnas.0404438101","article-title":"PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder","volume":"101","author":"Chen","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref1701","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2017.05.001","article-title":"A novel TRIP11-FLT3 fusion in a patient with a myeloid\/lymphoid neoplasm with eosinophilia","volume":"216-217","author":"Chung","year":"2017","journal-title":"Cancer Genet"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/leu.2016.304","article-title":"A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?","volume":"31","author":"Troadec","year":"2017","journal-title":"Leukemia"},{"key":"ref1711","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/leu.2016.304","article-title":"A novel t(3;13)(q13;q12) translocation fusing FLT3 with GOLGB1: toward myeloid\/lymphoid neoplasms with eosinophilia and rearrangement of FLT3?","volume":"31","author":"Troadec","year":"2017","journal-title":"Leukemia"},{"key":"ref1411","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"ref1231","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1038\/leu.2008.287","article-title":"Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias","volume":"22","author":"Gotlib","year":"2008","journal-title":"Leukemia"},{"key":"ref1161","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3324\/haematol.2008.005447","article-title":"T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome","volume":"94","author":"Helbig","year":"2009","journal-title":"Haematologica"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaci.2007.03.015","article-title":"Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance","volume":"120","author":"B\u00f6hm","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"key":"ref891","first-page":"1263","article-title":"Lack of response to imatinib mesylate in a patient with accelerated phase myeloproliferative disorder with rearrangement of the platelet-derived growth factor receptor beta-gene","volume":"89","author":"Bastie","year":"2004","journal-title":"Haematologica"},{"key":"ref1571","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/his.14097","article-title":"Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid\/lymphoid neoplasms","volume":"76","author":"Fang","year":"2020","journal-title":"Histopathology"},{"key":"ref1881","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"ref2061","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.2812.2812","article-title":"Limited efficacy of ponatinib in myeloproliferative neoplasms associated with FGFR1 fusion genes","volume":"126","author":"Kreil","year":"2015","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","article-title":"Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1","volume":"144","author":"Vega","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"ref1621","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"ref1961","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"key":"ref2101","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid\/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1 (FGFR1)","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jdv.12416","article-title":"Newly identified phenotypes in a FIP1L1\/PDGFRA-associated paediatric HES patient: thrombocytosis, mHPA, young stroke and blindness","volume":"29","author":"Zeng","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"key":"ref2001","first-page":"3027631","article-title":"von Clinical response to avapritinib by RECIST and Criteria in th line and exon gastrointestinal stromal tumors abstract Connective Tissue Oncology Meeting Japan Abstract","volume":"4","author":"HeinrichM","year":"2019","journal-title":"Society Annual"},{"key":"ref1261","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/hon.919","article-title":"Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study","volume":"28","author":"Helbig","year":"2010","journal-title":"Hematol Oncol"},{"key":"ref1841","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1365-2141.2008.07294.x","article-title":"Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study","volume":"143","author":"Metzgeroth","year":"2008","journal-title":"Br J Haematol"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cancergen.2017.05.001","article-title":"A novel TRIP11-FLT3 fusion in a patient with a myeloid\/lymphoid neoplasm with eosinophilia","volume":"216-217","author":"Chung","year":"2017","journal-title":"Cancer Genet"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/his.14097","article-title":"Systematic use of fluorescence in-situ hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid\/lymphoid neoplasms","volume":"76","author":"Fang","year":"2020","journal-title":"Histopathology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat Genet"},{"key":"ref781","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hoc.2017.04.009","article-title":"Tyrosine kinase inhibitors in the treatment of eosinophilic neoplasms and systemic mastocytosis","volume":"31","author":"Gotlib","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref2091","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41409-019-0436-1","article-title":"Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"54","author":"Katagiri","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref1021","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-020-01330-y","article-title":"Pemigatinib: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"key":"ref1741","doi-asserted-by":"crossref","first-page":"e0185602","DOI":"10.1371\/journal.pone.0185602","article-title":"Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"ref1131","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1309\/AJCPMORR5Z2IKCEM","article-title":"Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1","volume":"144","author":"Vega","year":"2015","journal-title":"Am J Clin Pathol"},{"key":"ref1991","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","article-title":"PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia","volume":"131","author":"Zhang","year":"2018","journal-title":"Blood"},{"key":"ref1001","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41409-019-0436-1","article-title":"Maintenance 5-azacytidine therapy by MRD monitoring after allogeneic HSCT in myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"54","author":"Katagiri","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"ref861","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/leu.2011.181","article-title":"Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation","volume":"26","author":"Metzgeroth","year":"2012","journal-title":"Leukemia"},{"key":"ref1201","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.hoc.2017.04.009","article-title":"Tyrosine kinase inhibitors in the treatment of eosinophilic neoplasms and systemic mastocytosis","volume":"31","author":"Gotlib","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref2131","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2012.066407","article-title":"Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome","volume":"98","author":"Chase","year":"2013","journal-title":"Haematologica"},{"key":"ref1921","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3324\/haematol.11420","article-title":"The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study","volume":"92","author":"Baccarani","year":"2007","journal-title":"Haematologica"},{"key":"ref1871","doi-asserted-by":"crossref","first-page":"33229","DOI":"10.18632\/oncotarget.8906","article-title":"Long-term outcomes of imatinib in patients with FIP1L1\/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China","volume":"7","author":"Qu","year":"2016","journal-title":"Oncotarget"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/sj.leu.2404266","article-title":"FLT3 is fused to ETV6 in a myeloproliferative disorder with hypereosinophilia and a t(12;13)(p13;q12) translocation","volume":"20","author":"Vu","year":"2006","journal-title":"Leukemia"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"ref1471","first-page":"177","article-title":"Detection of the FIP1L1-PDGFRA fusion in idiopathic hypereosinophilic syndrome and chronic eosinophilic leukemia","volume":"125","author":"Cools","year":"2006","journal-title":"Methods Mol Med"},{"key":"ref1861","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/leu.2012.162","article-title":"Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome","volume":"26","author":"Pardanani","year":"2012","journal-title":"Leukemia"},{"key":"ref1331","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia\/lymphoma syndrome","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat Genet"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br J Haematol"},{"key":"ref791","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"ref1291","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/jdv.12416","article-title":"Newly identified phenotypes in a FIP1L1\/PDGFRA-associated paediatric HES patient: thrombocytosis, mHPA, young stroke and blindness","volume":"29","author":"Zeng","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref2011","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s40265-020-01275-2","article-title":"Avapritinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref2081","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/leu.2015.136","article-title":"Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia","volume":"30","author":"Khodadoust","year":"2016","journal-title":"Leukemia"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.humpath.2009.11.003","article-title":"8p11 myeloproliferative syndrome: a review","volume":"41","author":"Jackson","year":"2010","journal-title":"Hum Pathol"},{"key":"ref1601","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1182\/blood.V95.5.1788.005k15_1788_1796","article-title":"FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33)","volume":"95","author":"Guasch","year":"2000","journal-title":"Blood"},{"key":"ref1281","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1097\/MPH.0b013e31827e6386","article-title":"FIP1L1-PDGFR\u03b1-positive hypereosinophilic syndrome in childhood: a case report and review of literature","volume":"36","author":"Farruggia","year":"2014","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref1091","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/ehm.11.81","article-title":"Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field","volume":"5","author":"Valent","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"ref1111","doi-asserted-by":"crossref","first-page":"259","DOI":"10.5858\/arpa.2011-0597-RA","article-title":"Diagnostic complexities of eosinophilia","volume":"137","author":"Montgomery","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.cancergen.2020.03.002","article-title":"Myeloid neoplasm with a novel cryptic PDGFRB rearrangement detected by next-generation sequencing","volume":"244","author":"Zimmermann","year":"2020","journal-title":"Cancer Genet"},{"key":"ref1651","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/gcc.20235","article-title":"A BCR-JAK2 fusion gene as the result of a t(9;22)(p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia","volume":"44","author":"Griesinger","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"ref71","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"ref1011","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110388","article-title":"Interim results from Fight-203, a phase 2, open-label, multicenter study evaluating the efficacy and safety of pemigatinib (INCB054828) in patients with myeloid\/lymphoid neoplasms with rearrangement of fibroblast growth factor receptor 1 (FGFR1)","volume":"132","author":"Verstovsek","year":"2018","journal-title":"Blood"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1158\/0008-5472.CAN-04-4263","article-title":"The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2","volume":"65","author":"Reiter","year":"2005","journal-title":"Cancer Res"},{"key":"ref1381","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"7248","DOI":"10.1038\/sj.onc.1208850","article-title":"The t(8;9)(p22;p24) translocation in atypical chronic myeloid leukaemia yields a new PCM1-JAK2 fusion gene","volume":"24","author":"Bousquet","year":"2005","journal-title":"Oncogene"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1016\/j.exphem.2007.07.002","article-title":"A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy","volume":"35","author":"Grand","year":"2007","journal-title":"Exp Hematol"},{"key":"ref1221","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1080\/10428194.2018.1480774","article-title":"Cryptic ETV6-PDGFRB fusion in a highly complex rearrangement of chromosomes 1, 5, and 12 due to a chromothripsis-like event in a myelodysplastic syndrome\/myeloproliferative neoplasm","volume":"60","author":"Singh","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref931","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.23588","article-title":"Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome","volume":"89","author":"Helbig","year":"2014","journal-title":"Am J Hematol"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000497348","article-title":"RNA sequencing analysis for the identification of a PCM1\/PDGFRB fusion gene responsive to imatinib","volume":"142","author":"Such","year":"2019","journal-title":"Acta Haematol"},{"key":"ref761","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2013.129","article-title":"Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid\/lymphoid neoplasms with PDGFR rearrangements in blast phase","volume":"27","author":"Metzgeroth","year":"2013","journal-title":"Leukemia"},{"key":"ref871","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1038\/leu.2012.8","article-title":"Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases","volume":"26","author":"Lierman","year":"2012","journal-title":"Leukemia"},{"key":"ref2141","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1200\/JCO.2012.46.4370","article-title":"Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene","volume":"31","author":"Rumi","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref1721","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"key":"ref1761","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.3324\/haematol.2017.187302","article-title":"Molecular genetic characterization of myeloid\/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2","volume":"103","author":"Baer","year":"2018","journal-title":"Haematologica"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/9\/article-p1248.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/9\/article-p1248.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T02:16:03Z","timestamp":1723515363000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/9\/article-p1248.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":218,"journal-issue":{"issue":"9"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.0042","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]}}}